News headlines about Agenus (NASDAQ:AGEN) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agenus earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.3678923616825 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern’s rankings:
- Another ‘Picks And Shovels’ Nasdaq Stock With Massive Potential (nasdaq.com)
- New shingles vaccine gets FDA panel votes (news-medical.net)
- GSK’s Shingrix containing Agenus’ QS-21 Stimulon® adjuvant receives Unanimous FDA Advisory Committee … – PR Newswire (press release) (prnewswire.com)
- GSK’s Shingrix containing Agenus’ QS-21 Stimulon® adjuvant receives Unanimous FDA Advisory Committee … – GuruFocus.com (gurufocus.com)
- Before You Buy Agenus Inc’s (AGEN), You Should Consider This (finance.yahoo.com)
Shares of Agenus (NASDAQ AGEN) traded up 1.22% on Friday, hitting $4.15. 445,801 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $3.87 and its 200 day moving average price is $3.86. The company’s market cap is $413.80 million. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49.
Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.04. The company had revenue of $4.21 million for the quarter, compared to analyst estimates of $6.66 million. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. Agenus’s quarterly revenue was down 36.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.33) EPS. On average, equities research analysts expect that Agenus will post ($1.13) earnings per share for the current year.
AGEN has been the topic of a number of research reports. ValuEngine cut shares of Agenus from a “sell” rating to a “strong sell” rating in a report on Saturday, July 8th. Zacks Investment Research raised shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Wednesday, July 5th. BidaskClub raised shares of Agenus from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $7.00 target price on shares of Agenus in a research note on Friday, August 4th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $5.88.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with our FREE daily email newsletter.